ESCAPE Bio
Escape Bio is a clinical-stage biopharmaceutical company that develops small molecule drugs intended to treat neurodegenerative diseases. The company is developing therapeutics for the novel, precisely therapies for genetic neurodegenerative diseases. Escape Bio's pipeline includes candidates targeting known genetic drivers of multiple diseases, including ESB1609, a small molecule S1P5 receptor agonist for the treatment of CNS lysosomal storage disorders and ESB5070, a small molecule kinase inhibitor for Parkinson’s disease patients who have an LRRK2 G2019S variant and an Alzheimer's disease program targeting ApoE4. E-scape Bio was founded in 2015 and is headquartered in San Francisco, California, United States.
Domain
e-scapebio.com
Country
United StatesIndustry
BiotechnologyEmployees
11-50
Last Funding
$73.0M
Founded
2014
Tech Stack (10 technologies)
Frequently Asked Questions
What technologies does ESCAPE Bio use?+
ESCAPE Bio uses 10 technologies including Odoo, Backdrop, Popper.
What industry is ESCAPE Bio in?+
ESCAPE Bio operates in the Biotechnology industry.
Where is ESCAPE Bio based?+
ESCAPE Bio is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026